The Pharma Data

MARCH 25, 2021

SG is a first-in-class therapy targeting Trop-2, a protein frequently expressed in multiple types of epithelial tumors, such as TNBC, where high expression is associated with poor survival and relapse. More information about ASCENT is available at [link]. About Sacituzumab Govitecan-Hziy.

Genotoxicity 52

Genotoxicity Genotype Containment Protein 52

The Pharma Data

JANUARY 26, 2021

Vir Biotechnology , Eli Lilly and GlaxoSmithKline struck a three-way collaborative deal to evaluate Vir’s investigational monoclonal antibody, VIR-7831, in combination with Lilly’s bamlanivimab in low-risk patients with mild to moderate COVID-19. Eli Lilly’s bamlanivimab targets different sites on the SARS-CoV-2 spike protein.

Antibody 52

Antibody Genotype Trials Nurses 52

The Pharma Data

APRIL 7, 2021

Trodelvy is directed to the Trop-2 receptor, a protein frequently expressed in multiple types of epithelial tumors, including TNBC, where high expression is associated with poor survival and relapse. Trodelvy also extended median overall survival (OS) to 11.8 months vs. 6.9 months (HR: 0.51; 95% CI: 0.41-0.62; About Trodelvy.

HR 52

HR Genotype FDA Approval Genotoxicity 52

The Pharma Data

APRIL 14, 2021

The incidence of Grade 3-4 neutropenia in genotyped patients was 67% in patients homozygous for the UGT1A1*28, 46% in patients heterozygous for the UGT1A1*28 allele and 46% in patients homozygous for the wild-type allele. More information on TROPiCS-04 is available at [link]. About Trodelvy.

Genotype 52

Genotype Containment FDA Approval Genotoxicity 52